Blue Jet Healthcare Limited
NSE: BLUEJET BSE: BLUEJET
Prev Close
406.95
Open Price
435
Volume
500,633
Today Low / High
419.1 / 439.8
52 WK Low / High
392 / 1027.8
Range
401 - 443
Prev Close
406.44999
Open Price
446.89999
Volume
22,751
Today Low / High
420.2 / 446.9
52 WK Low / High
393 / 1028.2
Range
402 - 444
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 422 (target range: 401 - 443), reflecting a change of 15.05 (3.69824%). On the BSE, it is listed at 423.3 (target range: 402 - 444), showing a change of 16.85001 (4.14565%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Blue Jet Healthcare Limited Graph
Blue Jet Healthcare Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Blue Jet Healthcare Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 422.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 423.30 | 427.53 | 384.78 - 470.29 |
| 431.77 | 345.41 - 518.12 | ||
| 436.00 | 305.20 - 566.80 | ||
| Bearish Scenario | 423.30 | 419.07 | 377.16 - 460.97 |
| 414.83 | 331.87 - 497.80 | ||
| 410.60 | 287.42 - 533.78 |
Overview of Blue Jet Healthcare Limited
ISIN
INE0KBH01020
Industry
Biotechnology
Vol.Avg
409,498
Market Cap
73,202,409,350
Last Dividend
1.2
Official Website
IPO Date
2023-11-01
DCF Diff
-115.83
DCF
539
Financial Ratios Every Investor Needs
Stock Dividend of BLUEJET
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-19 | September 19, 25 | 1.2 | 1.2 | 2025-09-19 | 2025-10-25 | |
| 2024-09-17 | September 17, 24 | 1 | 1 | 2024-09-18 | 2024-10-24 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,029.99 Cr | 461.22 Cr | 568.76 Cr | 0.5522 | 0.00 Cr | 10.85 Cr | 359.94 Cr | 305.20 Cr | 17.59 | 423.99 Cr | 0.2963 |
| 2024-03-31 | 710.32 Cr | 321.19 Cr | 389.13 Cr | 0.5478 | 0.00 Cr | 7.62 Cr | 337.22 Cr | 163.75 Cr | 9.44 | 248.35 Cr | 0.2305 |
| 2023-03-31 | 718.48 Cr | 448.16 Cr | 270.32 Cr | 0.3762 | 0.00 Cr | 5.44 Cr | 196.36 Cr | 160.03 Cr | 9.23 | 243.04 Cr | 0.2227 |
| 2022-03-31 | 676.78 Cr | 380.20 Cr | 296.58 Cr | 0.4382 | 0.00 Cr | 4.15 Cr | 222.43 Cr | 181.59 Cr | 10.47 | 268.68 Cr | 0.2683 |
| 2021-03-31 | 494.21 Cr | 246.73 Cr | 247.48 Cr | 0.5008 | 0.00 Cr | 6.39 Cr | 185.12 Cr | 138.42 Cr | 7.98 | 215.46 Cr | 0.2801 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 119.79 Cr | 1,417.53 Cr | 284.42 Cr | 1,133.1110 Cr | 19.99 Cr | -99.80 Cr | 263.92 Cr | 388.94 Cr | 0.45 Cr | 0.00 Cr | 0.00 Cr | 255.9070 Cr |
| 2024-03-31 | 40.95 Cr | 1,058.85 Cr | 213.62 Cr | 845.2230 Cr | 1.61 Cr | -39.34 Cr | 129.84 Cr | 318.80 Cr | 0.00 Cr | 0.00 Cr | 15.00 Cr | 205.9640 Cr |
| 2023-03-31 | 65.44 Cr | 862.07 Cr | 180.58 Cr | 681.4860 Cr | 6.83 Cr | -58.61 Cr | 129.14 Cr | 193.41 Cr | 0.02 Cr | 0.00 Cr | 0.00 Cr | 173.8790 Cr |
| 2022-03-31 | 75.37 Cr | 713.38 Cr | 191.83 Cr | 521.5420 Cr | 22.84 Cr | -52.53 Cr | 105.70 Cr | 161.92 Cr | 0.04 Cr | 0.00 Cr | 0.00 Cr | 174.5040 Cr |
| 2021-03-31 | 61.13 Cr | 536.28 Cr | 196.46 Cr | 339.8180 Cr | 51.62 Cr | -8.01 Cr | 118.62 Cr | 144.91 Cr | 7.41 Cr | 0.01 Cr | 0.00 Cr | 163.1050 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 45.7650 Cr | -35.1830 Cr | -18.5570 Cr | -34.1150 Cr | -7.9750 Cr | 32.9790 Cr | -79.8800 Cr | 305.2030 Cr | -1.1120 Cr | -17.3490 Cr | -134.0880 Cr |
| 2024-03-31 | 241.2570 Cr | -263.7550 Cr | -1.9860 Cr | 66.9590 Cr | -24.4840 Cr | 40.9540 Cr | -174.2980 Cr | 163.7510 Cr | -1.8250 Cr | -0.0020 Cr | -4.1770 Cr |
| 2023-03-31 | 141.5500 Cr | -147.2520 Cr | -4.2330 Cr | 82.2790 Cr | -9.9350 Cr | 65.4380 Cr | -59.2710 Cr | 160.0270 Cr | -2.8800 Cr | -0.0020 Cr | -20.6270 Cr |
| 2022-03-31 | 146.4170 Cr | -76.0260 Cr | -56.1450 Cr | 120.7510 Cr | 14.2460 Cr | 75.3730 Cr | -22.9220 Cr | 181.5910 Cr | -52.5580 Cr | -0.0020 Cr | 12.6850 Cr |
| 2021-03-31 | 129.9170 Cr | -56.6480 Cr | -22.1900 Cr | 80.7670 Cr | 51.0550 Cr | 61.1270 Cr | -49.1500 Cr | 141.6160 Cr | -22.2430 Cr | -0.0020 Cr | -48.6990 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 165.48 Cr | 82.29 Cr | 83.20 Cr | 0.5027 | 49.08 Cr | 52.14 Cr | 3.01 | 79.22 Cr | 0.3151 |
| 2025-06-30 | 354.76 Cr | 182.90 Cr | 171.86 Cr | 0.4844 | 115.30 Cr | 91.17 Cr | 5.26 | 129.25 Cr | 0.2570 |
| 2025-03-31 | 340.45 Cr | 153.47 Cr | 186.97 Cr | 0.5492 | 135.02 Cr | 110.10 Cr | 6.35 | 139.47 Cr | 0.3234 |
| 2024-12-31 | 318.38 Cr | 144.42 Cr | 173.96 Cr | 0.5464 | 119.27 Cr | 98.98 Cr | 5.71 | 137.26 Cr | 0.3109 |
| 2024-09-30 | 208.26 Cr | 109.53 Cr | 98.73 Cr | 0.4741 | 64.87 Cr | 58.35 Cr | 3.36 | 81.56 Cr | 0.2802 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 200.93 Cr | 210.40 Cr | 411.33 Cr | 311.83 Cr | 196.79 Cr | 990.06 Cr | 460.66 Cr | 1,527.46 Cr | 271.74 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 306.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,133.11 Cr |
| 2025-03-31 | 119.79 Cr | 186.69 Cr | 306.48 Cr | 349.53 Cr | 263.92 Cr | 1,005.95 Cr | 388.94 Cr | 1,417.53 Cr | 284.42 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 364.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -924.00 Cr |
| 2024-09-30 | 29.83 Cr | 334.58 Cr | 374.31 Cr | 211.56 Cr | 178.03 Cr | 795.66 Cr | 352.69 Cr | 1,181.03 Cr | 257.03 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 91.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 110.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 98.98 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 58.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 37.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹372.00 | ₹479,555,187,828.00 | ₹4,837,860.00 |
| Anthem Biosciences Ltd. | ANTHEM | ₹609.00 | ₹342,020,521,059.00 | ₹264,470.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹161.09 | ₹213,181,252,211.00 | ₹3,828,538.00 |
| Syngene International Limited | SYNGENE | ₹476.40 | ₹191,394,549,898.00 | ₹1,991,388.00 |
| Onesource Specialty Pharma Ltd. | ONESOURCE | ₹1,180.30 | ₹135,244,840,742.00 | ₹394,478.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,168.00 | ₹122,191,726,272.00 | ₹139,750.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹666.00 | ₹105,235,249,410.00 | ₹363,399.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹422.00 | ₹73,202,409,350.00 | ₹500,633.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹693.20 | ₹55,790,676,960.00 | ₹157,591.00 |
| Zota Health Care Limited | ZOTA | ₹1,291.10 | ₹39,162,490,871.00 | ₹40,302.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹229.20 | ₹35,934,685,374.00 | ₹376,627.00 |
Key Executives
Gender: male
Year Born: 1963
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1965
Gender: male
Year Born:
Gender: male
Year Born: 1993
Gender: male
Year Born:
Gender: female
Year Born: 1969
Gender: female
Year Born:
Gender: female
Year Born:
FAQs about Blue Jet Healthcare Limited
The CEO is Akshay Bansarilal Arora.
The current price is ₹422.00.
The range is ₹392-1027.8.
The market capitalization is ₹7,320.24 crores.
The dividend yield is 0.28%.
The P/E ratio is 20.77.
The company operates in the Healthcare sector.
Overview of Blue Jet Healthcare Limited (ISIN: INE0KBH01020) is a leading Biotechnology in India. With a market capitalization of ₹7,320.24 crores and an average daily volume of 409,498 shares, it operates in the Biotechnology. The company last declared a dividend of ₹1.2.